Continuing Education Activities
Here at JADPRO CE, you can find a valuable array of certified educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!
CAR T-Cell Therapy and the Pharmacology of Managing Cytokine Release Syndrome
Learn from two experts on how to identify patients who meet criteria as candidates for CAR T-cell therapy and apply strategies to mitigate associated serious side effects, including cytokine release syndrome.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing Therapies in Indolent Lymphomas (FL and CLL)
Discover current best practices for treating follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), including monitoring patients with CLL for 17p deletion at diagnosis and throughout the course of the disease and current and emerging data supporting combination therapies in CLL and novel targeted therapies for newly diagnosed and relapsed/refractory FL.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Therapeutic Advances in Prostate Cancer
Learn from two experts in the field of prostate cancer as they discuss clinical data of emerging and current agents for the treatment of non-metastatic castration-resistant prostate cancer for rapidly rising prostate-specific antigen levels, the role of docetaxel and abiraterone in newly diagnosed metastatic disease, emerging data on the role of genomics in metastatic castration-sensitive and -resistant disease, and strategies to manage toxicities of current and emerging treatments.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma
Discover how to prevent and mitigate adverse events of established and emerging cytotoxic regimens, novel agents, and checkpoint inhibitors used to treat classical Hodgkin lymphoma, including best practices and emerging data.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Directions in Myeloid Malignancies
Review strategies to monitor minimal residual disease in myeloid malignancies, as well as the safety and efficacy of novel treatment approaches and associated mutations such as IDH2, TP53, FLT3, BCL2, and cell surface antigen CD33.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing of Treatments for Patients With Ovarian Cancer
Take a deep dive into the history of ovarian cancer treatment, evaluate current options for first-line and maintenance therapy, and review safety and efficacy data for PARP inhibitors alone and in combination with immunotherapy or anti-angiogenic agents.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Drug Updates in Hematologic Malignancies
Discover the latest pharmacology and indication approvals for the management of patients with hematologic malignancies, including pivotal clinical trial data, associated signs and symptoms of serious or life-threatening adverse effects, and the impact of these agents in advanced practice.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Differential Diagnosis and Testing for Hematologic Malignancies
With the backdrop of three unique, real-life case studies, learn how to interpret advancements in diagnostic tests used in risk stratification for hematologic malignancies, including next-generation sequencing for the discovery of novel molecular abnormalities as defined by the World Health Organization and European Leukemia Network.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Advancing the Management of Plasma Cell Dyscrasias
Through expert, case-based discussion, learn how to interpret differential diagnoses of plasma cell dyscrasias, implement the recent changes in the clinical management of the spectrum of multiple myeloma, evaluate the risks and benefits of early treatments for smoldering myeloma, and plan management strategies for patients with solitary plasmacytomas and amyloidosis.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology
Discover strategies to mitigate adverse events (AEs) of checkpoint inhibitors and radiotherapy for patients with thoracic cancer, and review emerging data regarding managing AEs of EGFR and ALK inhibitors.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Drug Updates in Solid Tumors
Review the pharmacology and approved indications of medications for the management of solid tumors, including pivotal clinical trial data, the signs and symptoms of associated serious or life-threatening adverse effects, and each drug’s impact on advanced practice.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Evolving Therapies in the Clinical Management of Melanoma
Take a deep dive into clinical data supporting immunotherapies and emerging targeted therapies for the treatment of advanced/metastatic melanoma, as well as strategies to manage and mitigate associated adverse events.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Preventing and Treating Venous Thrombosis in Oncology
Discover how to interpret recent findings comparing safety and efficacy of “standard” anticoagulants with those of direct oral anticoagulants (DOACs), evaluate the risks and benefits of treatment of DOACs, and monitor and assess patient response to anticoagulant treatment.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing Therapies in Renal Cell Carcinoma
Review strategies for how to best utilize immunotherapy in renal cell carcinoma, including tyrosine kinase inhibitors in the adjuvant setting in patients with advanced disease.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents
This presentation reviews current treatments for early-stage and relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma. Emerging therapies, including CAR T-cell therapy, along with patient selection criteria and toxicities unique to new treatments are addressed as well.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 1 hour and 30 minutes
Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents
Dive into current strategies for managing patients with chronic lymphocytic leukemia and follicular lymphoma, including the risk-adapted treatment selection of new therapies based on factors such as patient age, performance status, and comorbidities. The latest data on the efficacy and safety of newly approved agents are presented, and strategies to treat common side effects reviewed.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 1 hour
Emerging Therapies for Multiple Myeloma
The overall survival of patients with multiple myeloma has increased within the past decade, thanks to newer agents such as immunomodulatory drugs and proteasome inhibitors. Receive updated data on key FDA approvals and practice updates for maximizing therapies while mitigating adverse events.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 45 minutes
Emerging Therapies for Hodgkin Lymphoma
In this lecture, learn about the principles of treatment for relapsed/refractory classical Hodgkin lymphoma, including therapeutic targets and mechanisms of action of newly approved agents in order to educate and manage patients effectively. Hear from an expert in the field on best practices for treating immune-related adverse events such as pneumonitis, hyperthyroidism, and colitis.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 30 minutes
Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms
Get an overview of the diagnostic criteria and key clinical trials for Philadelphia chromosome–negative classical myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. Learn about the role of the JAK-STAT signaling pathway, as well as strategies for optimizing the selection and sequencing of treatments for patients with myeloproliferative neoplasms.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 1 hour
Risk-Adapted Treatment of Acute Myelogenous Leukemia
Acute myeloid leukemia is a heterogenous group of distinct malignancies that accounts for 80% of acute leukemias in adults. Recent advancements in diagnostic tests, such as next-generation sequencing, have led to the identification of unique biomarkers associated with acute myeloid leukemia. These advancements, along with new targeted therapies, offer hope for a greater impact of survival for patients with this disease.
Posted: 7/16/2018 / Expires: 7/16/2019
Estimated time to complete: 1 hour and 15 minutes
Overview of the Immune System and Immune Checkpoint Targets and Their Mechanisms of Action
This lecture provides a comprehensive overview of the immune system and current immunotherapeutic strategies, including discussions on the difference between innate and adaptive immunity, significance of neoantigens, and emerging checkpoint inhibitors.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 45 minutes
Immunotherapy: Treatment-Related Issues
There are several treatment-related issues that advanced practitioners caring for patients with cancer should be aware of. Factors predictive of response to immunotherapy, different combinations of treatments, and immunotherapy response patterns are reviewed.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 45 minutes
Immune-Related Adverse Events
Immunotherapy has been the source of promising new cancer treatments, but carries with it a host of side effects that can affect any organ system. The range of possible side effects makes it important for advanced practitioners to understand the timing and incidence of immune-related adverse events, as well as to recognize and manage these adverse events for patients to receive the full benefit of their treatment.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 1 hour
Renal Cell Carcinoma
40% of patients develop metastasis after primary surgical resection of localized renal cell carcinoma (RCC); this signifies an unmet need for the treatment of metastatic RCC. The mainstay of treatment has been antiangiogenic agents for previously untreated patients, and nivolumab has been shown to improve survival for patients who received prior antiangiogenic therapy. Details on the clinical trial upon which FDA approval for nivolumab was based on, as well as a case study illustrating how to appropriately manage immune-related dermatitis and arthritis are discussed in this video.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 30 minutes
Non-Small Cell Lung Cancer
The role of immunotherapy in non–small cell lung cancer has been rapidly expanding as results from several clinical trials have come out in recent years. Takeaways from these studies and a differential diagnosis of a case study patient with anemia and nephritis demonstrate key points advanced practitioners should be aware of when managing this patient population.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 45 minutes
Melanoma
Melanoma is one of the few malignancies where the incidence is on the rise. In this case-based lecture, approved immunotherapies for the treatment of patients with melanoma are discussed, and a case study of a patient with stage IV melanoma complaining of fever, cough, and shortness of breath is presented.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 30 minutes
Mismatch Repair Deficient (dMMR) and Microsatellite Instability-High (MSI-H) Tumors
The use of immune checkpoint inhibitors is emerging as an effective strategy to treat patients with mismatch repair–deficient and microsatellite instability–high tumors. This presentation summarizes data on currently available immunotherapeutic agents for these tumors and details the appropriate management of immune-related hypothyroidism.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 30 minutes
Metastatic Urothelial Carcinoma
After decades of no new approvals for the treatment of metastatic urothelial cancer, a malignancy associated with a low survival rate, novel immunotherapeutic agents are changing the treatment landscape for bladder cancer. Learn about the therapies showing activity in this malignancy and get clinical pearls on how to manage a patient with urothelial cancer with immune-related hepatitis and pancreatitis.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 30 minutes
Head and Neck Cancer
Data on currently available immunotherapeutic agents for recurrent/metastatic head and neck squamous cell carcinoma point to a new standard of care with immune checkpoint inhibitors. Listen to the latest results comparing these inhibitors to chemotherapy, and the symptoms, workup, diagnosis, and management of a head and neck squamous cell carcinoma patient with hypophysitis.
Posted: 6/28/2018 / Expires: 6/28/2019
Estimated time to complete: 30 minutes
Role of Antibody-Drug Conjugates for Front-Line Therapy in Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Nadia Khan, MD, discuss the role of antibody-drug conjugates in the treatment of classical Hodgkin lymphoma, including mechanism of action, recent approvals, emerging data, and expert guidance on clinical application.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Anticipating and Managing Side Effects for Patients With Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Barbara Rogers, CRNP, MN, AOCN®, ANP-BC, review best practices for anticipating and managing side effects for patients being treated for classical Hodgkin lymphoma, including the short- and long-term adverse events associated with chemotherapy, checkpoint inhibitors, and antibody–drug conjugates.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Shared Decision-Making: How to Discuss Therapeutic Options With Your Patients Considering Treatment for Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Kevin Nguyen, a patient who was treated for classical Hodgkin lymphoma, discuss his treatment journey from diagnosis through relapse and how shared decision-making between him and his health-care team played an important role in the process.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Understanding the Role of Targets and Pathways in the Treatment of Melanoma
Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.
Posted: 11/27/2018 / Expires: 11/27/2019
Estimated time to complete: 3 hours